Decapeptil is a drug from the group of gonadotropin-releasing hormone analogues.
Release form and composition
Decapeptyl is available in the form of a solution for subcutaneous administration.
The active component of the drug is triptorelin (in the form of acetate). The concentration of the substance in one milliliter of solution (in terms of pure substance) is 95.6 μg.
Auxiliary components of Decapeptila: glacial acetic acid, sodium chloride, water for injection.
Available in syringe ampoules. Each package is completed with seven syringes (1 ml each) and seven needles.
Indications for use
Dekapeptil is indicated for women for the treatment of fibroids and endometriosis. In combination with assisted reproductive technologies (ART), the drug is also prescribed for infertility (in vitro fertilization and, in particular, during the procedure of embryo transfer).
Men, in accordance with the instructions to Dekapeptil, means it is advisable to appoint for the symptomatic treatment of progressive hormone-dependent prostate cancer.
For women, use of Decapeptila is contraindicated during periods of pregnancy and breastfeeding, as well as in the presence of clinical manifestations of osteoporosis or an increased risk of its development.
The instructions to Decapeptil indicated that the drug should be prescribed with caution when conducting an ART program in women with polycystic ovaries, when the number of follicles determined by ultrasound exceeds 10.
For men, the drug is contraindicated in hormone-independent prostate cancer, as well as in the event that treatment was preceded by surgical castration.
Common to both men and women, contraindication is individual sensitivity to triptorelin or auxiliary components of Decapeptila.
Dosing and Administration
According to the instructions, Decapeptil is intended for subcutaneous administration.
When treating female infertility by in vitro fertilization, the solution is usually administered in a dose of 0.1 mg. The short protocol implies the administration of the drug on the first day of the menstrual cycle or on the first day of the early follicular phase prior to the administration of hCG (human chorionic gonadotropin). The ultrashort protocol involves injecting Decapeptil over three days from the first day of the menstrual cycle or the early follicular phase.
The starting dose for women with prostate carcinoma in men, as well as endometriosis and fibromyoma in women is 1 ml of solution (1 injection of 0.5 mg). The medicine is administered 1 time / day. subcutaneously during the week. Starting from the 8th day of the course, supportive therapy is indicated using Dekapeptil at a dose of 0.1 mg. Place of administration of the drug should be changed.
During the period of treatment with the drug Decapeptil the following side effects may occur:
- Decreased libido and potency;
- Mood lability;
- Impairment of visual perception;
- Bone pain caused by spinal compression injury;
- Pruritus and flushing of the skin;
- Pain associated with metastasis growth;
- Syndrome of pathological muscle fatigue;
- Back pain;
- An increase in the size of the lymph nodes;
- Obstruction of the urinary tract;
- Weight gain;
- Uterine bleeding;
- Pain during intercourse;
- Lack of appetite;
- Febrile states;
- Edema of the lower extremities;
- Increased vaginal mucosa dryness;
- Demineralization of bone tissue;
- Partial alopecia (alopecia);
- Sleep disturbance;
- Increased activity of liver enzymes;
- Decreased size of the testicles;
- Local soreness at the injection site of Dekapeptil.
Side effects are usually transient.
Data overdose Decapeptil not provided. In the case of the development of adverse events caused by the use of high doses of medication, symptomatic treatment is indicated.
Clinically significant drug interaction of Decapeptila with other drugs was not detected.
During the course of treatment, the concentration of sex hormones in the patient's blood should be constantly monitored.
Women at the time of initiation of treatment should exclude possible pregnancy. During therapy, the use of hormonal contraceptives, as well as estrogen-containing drugs, is considered unacceptable.
Each patient should be warned that during treatment with Dekapeptil menstrual bleeding will be absent. If the use of the drug regular menstruation occur, you should consult a doctor.
Therapy with this drug should be accompanied by regular ultrasound monitoring of the size of endometriotic nodes and uterine fibroids. Rapid downsizing can cause bleeding.
A transient increase in plasma testosterone concentrations in men can trigger a temporary deterioration in the patient’s condition. In most cases, poor health is manifested in the form of bone pain caused by metastases, muscle weakness, urinary tract obstruction, symptoms of spinal cord compression, an increase in the size of lymph nodes, and swelling of the legs. Any of these symptoms is a reason to go to a doctor.
In the initial stages of therapy, in some cases, it is considered expedient to prescribe antiandrogenic agents to the patient, the action of which is aimed at suppressing the symptoms associated with an increase in testosterone levels.
The structural analogue of Decapeptila is Diferelin.
A similar mechanism of action is characterized by Buserelin, Zoladex, Lyukrin Depot, Eligard.
Terms and conditions of storage
Decapeptil is a prescription drug from pharmacies.
Syringes-apmula with solution should be stored in the original packaging in a dark, out of reach of children. The optimum temperature is from 2 to 8 ºС. Shelf Life Decapeptila - 3 years.